Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773196 · ClinicalTrials.gov registry record
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
A clinical trial of Huntington Disease and Huntington's Dementia, sponsored by Sanguine Biosciences.
- Recruiting
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT05773196 is a study of Huntington Disease and Huntington's Dementia that is actively recruiting participants, run by Sanguine Biosciences. The registered enrollment target is 5 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05773196, a study of Huntington Disease and Huntington's Dementia, is actively recruiting participants, sponsored by Sanguine Biosciences.
- RECRUITING
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.
Conditions Studied
Interventions
- OTHER Biospecimen Collection
Study Locations (1)
Massachusetts
- Sanguine Biosciences, Inc. - Woburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2025-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05773196
The ClinicalTrials.gov registry entry for NCT05773196 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (99% lower). The listed sponsor is Sanguine Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT05773196 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05773196 about?
NCT05773196 is a clinical study titled "Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study". OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be...
What is the current status of trial NCT05773196?
This trial is currently recruiting. The enrollment target is 5 participants. The study started on 2023-03-14. Estimated completion is 2025-02-28.
What conditions does trial NCT05773196 study?
This clinical trial studies the following conditions: Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology).
What interventions are being tested in trial NCT05773196?
The interventions under investigation include: Biospecimen Collection (OTHER).
Who is sponsoring clinical trial NCT05773196?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05773196 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.